Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol
AssigneeZafgen, Inc.
InventorThomas E. Hughes
Life of this patent
Estimating the term…
Abstract
The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of, e.g., a MetAP-2 inhibitor.
Claims13
-63. (canceled)
A method for treating obesity in a human patient having an initial body mass index at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering once weekly to said patient about 1.8 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof.
A method for treating obesity in a human patient having an initial body mass index at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering once weekly to said patient about 2.5 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof.
A method for treating obesity in a human patient having an initial body mass index at least about 30 kg/m2, or at least about 27 kg/m2 and suffering from weight related co-morbidity, and in need thereof, comprising parenterally administering once weekly to said patient about 3.0 mg of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.